Treatment strategies for hepatitis C: making the best of limited options.
Where this comes from
- Record sourced from PubMed, PMID 10902236.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Data from two recent major trials suggest that several changes in clinical practice would benefit hepatitis C patients, including viral genotyping to more accurately determine the duration of therapy, and timely RNA measurement to predict treatment response. Although the combination of interferon alfa-2b and ribavirin therapy has proved superior to interferon alone, the success of interferon-based therapies in eradicating hepatitis C is limited, and the quest for new strategies and treatments continues.